InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: ku post# 269127

Wednesday, 07/27/2016 9:36:27 PM

Wednesday, July 27, 2016 9:36:27 PM

Post# of 345732
Reverse split talk should be shifted to YKT6 and its regulation in the release of exosomes and with this linked to the release of microRNAs....all in NSCLC as with Breast Cancer will provoke even the stingiest of BPs to close the deal with PS Targeting.

Is Barcelona Spain the only smart ones? I doubt it

I say some BPs are afraid to move to certain biomarkers because PS Targeting will win out over there as well... BPs in a losing situation here and maybe a license for one and for all is their only way out. Peregrine wins either way.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News